Biotech · Private company · New York, NY, US
Traverse Biotech Ii Inc
Track this companyFree. Adds Traverse Biotech Ii Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Development of a uPAR-Targeting Antibody-Drug Conjugate (ADC) for Pancreatic AdenocarcinomaFiscal year 2026 · $399.9KNIH RePORTER 1R43CA309866-01 · fetched Nov 12, 2026
- Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasisFiscal year 2025 · $297.7KNIH RePORTER 5R43AI181294-02 · fetched Nov 12, 2026
- Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasisFiscal year 2024 · $298.9KNIH RePORTER 1R43AI181294-01A1 · fetched Nov 12, 2026